论文部分内容阅读
目的:分析哌拉西林舒巴坦治疗脑卒中相关性肺炎的临床疗效。方法:选取2014年12月-2016年11月我院收治的脑卒中相关性肺炎患者70例,将所有患者随机分为两组,各35例。对照组采用左氧氟沙星治疗,观察组采用哌拉西林舒巴坦治疗,对比两组治疗有效率、治疗情况及不良反应发生率。结果:观察组治疗有效率明显高于对照组(94.29%vs 77.14%,P<0.05);观察组咳嗽缓解时间、退热时间均显著小于对照组(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:哌拉西林舒巴坦治疗脑卒中相关性肺炎临床效果显著,可有效缓解患者临床症状,治疗安全性高,在临床应用中值得推广。
Objective: To analyze the clinical efficacy of piperacillin-sulbactam in the treatment of stroke-associated pneumonia. Methods: Seventy patients with stroke-associated pneumonia admitted from December 2014 to November 2016 in our hospital were selected and all patients were randomly divided into two groups of 35 patients. The control group was treated with levofloxacin, and the observation group was treated with piperacillin-sulbactam. The treatment efficiency, treatment and incidence of adverse reactions were compared between the two groups. Results: The effective rate of observation group was significantly higher than that of the control group (94.29% vs 77.14%, P <0.05). The cough relief time and the antipyretic time in the observation group were significantly less than those in the control group (P <0.05) The difference was not statistically significant (P> 0.05). CONCLUSION: Piperacillin and sulbactam are effective in treating stroke-associated pneumonia, which can effectively relieve the clinical symptoms and have high safety in treatment. It is worthy of promotion in clinical application.